These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2402223)

  • 1. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
    Skalski V; Yarosh DB; Batist G; Gros P; Feindel W; Kopriva D; Panasci LC
    Mol Pharmacol; 1990 Sep; 38(3):299-305. PubMed ID: 2402223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
    Noë AJ; Malapetsa A; Panasci LC
    Cancer Res; 1994 Mar; 54(6):1491-6. PubMed ID: 8137253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
    Noë AJ; Malapetsa A; Panasci LC
    Mol Pharmacol; 1993 Jul; 44(1):204-9. PubMed ID: 8341272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transport of amino acid amide sarcosinamide and sarcosinamide chloroethylnitrosourea in human glioma SK-MG-1 cells.
    Skalski V; Feindel W; Panasci LC
    Cancer Res; 1990 May; 50(10):3062-6. PubMed ID: 1692254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity.
    Noë AJ; Marcantonio D; Barton J; Malapetsa A; Panasci LC
    Biochem Pharmacol; 1996 Jun; 51(12):1639-48. PubMed ID: 8687479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
    Skalski V; Feindel W; Panasci LC
    J Neurooncol; 1989 Jul; 7(2):189-93. PubMed ID: 2476532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines.
    Chen ZP; Remack J; Brent TP; Mohr G; Panasci LC
    Clin Cancer Res; 1999 Dec; 5(12):4186-90. PubMed ID: 10632359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.
    Chen ZP; Wang ZM; Carter CA; Alley MC; Mohr G; Panasci LC
    J Pharmacol Exp Ther; 2001 Mar; 296(3):712-5. PubMed ID: 11181897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
    Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
    Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H; Nguyen TH; Panasci L; Do P
    Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts.
    Malapetsa A; Bramson JL; Noë AJ; Panasci LC
    Cancer Chemother Pharmacol; 1992; 31(2):146-50. PubMed ID: 1280536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model.
    Chen ZP; Wang G; Huang Q; Sun ZF; Zhou LY; Wang AD; Panasci LC
    J Neurooncol; 1999 Aug; 44(1):7-14. PubMed ID: 10582663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
    Politi PM; Sinha BK
    Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and -independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo.
    Nguyen TH; Ong CK; Wong E; Leong CT; Panasci L; Huynh H
    Int J Oncol; 2005 Oct; 27(4):1131-40. PubMed ID: 16142332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
    Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
    Aida T; Bodell WJ
    Cancer Res; 1987 Mar; 47(5):1361-6. PubMed ID: 3469016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man.
    Skalski V; Rivas J; Panasci L; McQuillan A; Feindel W
    Cancer Chemother Pharmacol; 1988; 22(2):137-40. PubMed ID: 3409444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
    Mitsuki S; Diksic M; Conway T; Yamamoto YL; Villemure JG; Feindel W
    J Neurooncol; 1991 Feb; 10(1):47-55. PubMed ID: 1902507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
    Chen ZP; Pan J; Huang Q; Sun ZF; Zhou LY; Wang AD
    J Neurooncol; 2001 Jan; 51(1):19-24. PubMed ID: 11349876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.